Literature DB >> 20082850

Association of interleukin-23 receptor gene polymorphisms with risk of ovarian cancer.

Zhu Zhang1, Bin Zhou, Jian Zhang, Yue Chen, Ting Lai, Li Yan, Ailing Liang, Yi Li, Yanyun Wang, Yu Chen, Lin Zhang, Ming-Rong Xi.   

Abstract

Among gynecological malignancies, ovarian cancer is the leading cause of death. The overall 5-year survival rate remains poor, and the pathogenesis is unknown. The interleukin-23 receptor (IL23R) is known to be critically involved in the carcinogenesis of different malignant tumors. To assess the role of IL23R in ovarian cancer, we conducted a study to investigate the polymorphisms of the IL23R gene in 96 Han Chinese women with histologically proven ovarian cancer. Polymerase chain reaction-restriction fragment length polymorphism was used for genotyping. In all three single nucleotide polymorphisms of IL23R studied, the distribution of genotype and allele frequencies of rs10889677 differed significantly between patients and controls. The frequency of allele C of rs10889677 was significantly increased in cases compared with controls (0.281 vs. 0.183, odds ratio OR=1.752, 95% confidence interval CI=1.107-2.772). Furthermore, when stratified by tumor stage, we found that the allele frequencies of rs11465817 differed significantly between FIGO stage I+II and III+IV. The higher frequency of allele A was significantly associated with advanced ovarian cancer (P=0.027, OR=2.087, 95% CI=1.083-4.023). These findings indicate that IL23R polymorphisms may play an important role in the susceptibility and prognosis of ovarian cancer in the Chinese population. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20082850     DOI: 10.1016/j.cancergencyto.2009.09.006

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  8 in total

1.  Prognostic value of IL-27 polymorphisms and the susceptibility to epithelial ovarian cancer in a Chinese population.

Authors:  Zhu Zhang; Bin Zhou; Yuke Wu; Qianqian Gao; Kui Zhang; Yaping Song; Lin Zhang; Mingrong Xi
Journal:  Immunogenetics       Date:  2013-12-19       Impact factor: 2.846

2.  Association of interleukin-23 receptor gene polymorphisms with risk of bladder cancer in Chinese.

Authors:  Tielong Tang; Hui Xue; Shu Cui; Zhiyong Gong; Zhonghai Fei; Shulin Cheng; Chunyan Gui
Journal:  Fam Cancer       Date:  2014-12       Impact factor: 2.375

3.  Knockdown of stat3 expression by RNAi inhibits in vitro growth of human ovarian cancer.

Authors:  Shu-Hua Zhao; Fan Zhao; Jing-Ying Zheng; Li-Fang Gao; Xue-Jian Zhao; Man-Hua Cui
Journal:  Radiol Oncol       Date:  2011-04-28       Impact factor: 2.991

4.  Role of IL-12p40 in cervical carcinoma.

Authors:  H J M A A Zijlmans; S Punt; G J Fleuren; J B Trimbos; G G Kenter; A Gorter
Journal:  Br J Cancer       Date:  2012-10-25       Impact factor: 7.640

5.  Functional polymorphisms in interleukin-23 receptor and susceptibility to esophageal squamous cell carcinoma in Chinese population.

Authors:  Bin Ni; Shaomu Chen; Hongya Xie; Haitao Ma
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

6.  Functional IL-23R rs10889677 genetic polymorphism and risk of multiple solid tumors: a meta-analysis.

Authors:  Shanliang Zhou; Yueqin Ruan; Hongchen Yu; Yunzhi Chen; Yongjun Yao; Yanhui Ma; Yan Gao
Journal:  PLoS One       Date:  2013-11-20       Impact factor: 3.240

Review 7.  Association of IL-23R Polymorphisms (rs6682925, rs10889677, rs1884444) With Cancer Risk: A PRISMA-Compliant Meta-Analysis.

Authors:  Xing-Han Liu; Zhi-Ming Dai; Hua-Feng Kang; Shuai Lin; Xiao-Bin Ma; Meng Wang; Kang Liu; Cong Dai; Xi-Jing Wang; Zhi-Jun Dai
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

8.  Associations of Functional MicroRNA Binding Site Polymorphisms in IL23/Th17 Inflammatory Pathway Genes with Gastric Cancer Risk.

Authors:  Kaiyan Dong; Yajuan Xu; Qian Yang; Jiachen Shi; Jicheng Jiang; Yi Chen; Chunhua Song; Kaijuan Wang
Journal:  Mediators Inflamm       Date:  2017-10-08       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.